Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

Terns Pharmaceuticals (TERN) Amortizatization of Intangibles (2022 - 2023)

Terns Pharmaceuticals' Amortizatization of Intangibles history spans 2 years, with the latest figure at $148000.0 for Q4 2023.

For Q4 2023, Amortizatization of Intangibles rose 5.71% year-over-year to $148000.0; the TTM value through Dec 2023 reached $589000.0, up 7.48%, while the annual FY2025 figure was $411000.0, 28.77% down from the prior year.
Amortizatization of Intangibles reached $148000.0 in Q4 2023 per TERN's latest filing, down from $150000.0 in the prior quarter.
In the past five years, Amortizatization of Intangibles ranged from a high of $150000.0 in Q3 2023 to a low of $131000.0 in Q2 2022.